Teleflex stock performance and recent context
Teleflex (TFX) has drawn fresh attention after recent price moves, with the stock last closing at $131.68. For investors, the key question is how current performance aligns with the underlying medical device business.
See our latest analysis for Teleflex.
The recent 6.9% 1 day share price return and 14.0% 30 day share price return indicate short term momentum is building, yet the 3 year total shareholder return of 45.9% decline highlights how far the stock has fallen over a longer horizon.
If Teleflex’s move has you rethinking your healthcare exposure, this can be a good moment to scan for other medical technology opportunities through 35 healthcare AI stocks
With Teleflex trading at $131.68, an indicated intrinsic discount of about 45%, and only a small gap to the average analyst price target, investors have to ask whether this is a genuine mispricing or whether the market already recognizes future growth potential.
Most Popular Narrative: 1.9% Overvalued
Teleflex’s most followed narrative pegs fair value at $129.25, slightly below the last close at $131.68, which puts its long term story under the microscope.
The company's focus on portfolio optimization and potential separation or sale of business segments (e.g., NewCo), with anticipated proceeds deployed for debt paydown and shareholder returns, could unlock value and increase net margins and EPS through a more focused, streamlined operating model.
Want to see what is baked into that $129.25 figure? Revenue forecasts, margin rebuild, and a future earnings multiple all pull in the same direction.
Result: Fair Value of $129.25 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this depends on UroLift weakness and the integration risk around the BIOTRONIK vascular acquisition not negatively affecting earnings more than analysts currently expect.
Find out about the key risks to this Teleflex narrative.
Another angle on value
The narrative-driven fair value of $129.25 suggests Teleflex is slightly overvalued, yet our DCF model points in a different direction. On that view, the stock at $131.68 trades below an estimated future cash flow value of $238.50. This raises a very different question about upside and risk.
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Teleflex for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
Uncertain whether the mixed signals in this story point to opportunity or risk for you personally? Act while the data is fresh and weigh the trade offs using the 1 key reward and 4 important warning signs
Looking for more investment ideas?
If Teleflex has sharpened your thinking, do not stop here. Broaden your watchlist now so you are not late to the next opportunity.
- Target potential upside by scanning 51 high quality undervalued stocks that pair quality with share prices that may sit below their fundamentals.
- Strengthen your income stream by reviewing 12 dividend fortresses that aim for yields of 5% or more with an emphasis on resilience.
- Protect your downside by focusing on 72 resilient stocks with low risk scores that score well on financial stability and business risk.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com